Navigation Links
Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
Date:2/27/2008

PALATINE, Ill., Feb. 27 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) announced that President and Chief Executive Officer Andy Reddick has begun a leave of absence for health reasons for an as-yet undetermined period. Mr. Reddick will continue to serve as a member of the Company's Board of Directors. At the same time, the Company announced that Richard Markham has been appointed to serve as non-executive Chairman of the Board. Mr. Markham has been a member of our Board of Directors since May, 2006. Since November 2004 Mr. Markham has served as a partner at Care Capital, LLC, a venture capital firm that primarily invests in life sciences companies. From May 2002 until August 2004, Mr. Markham was the Vice Chairman of the Management Board and Chief Operating Officer of Aventis SA. From December 1999 until May 2002 he was the Chief Executive Officer of Aventis Pharma AG. Previously he was the Chief Executive Officer of Hoechst Marion Roussel, the President and Chief Operating Officer of Marion Merrell Dow, Inc. and a member of its board of directors. From 1973 to 1993 Mr. Markham was associated with Merck & Co. Inc., culminating in his position as President and Chief Operating Officer.

The Company's Board of Directors, management and staff all wish Mr. Reddick a full and speedy recovery and look forward to his return as soon as possible.

About Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion(R) (abuse deterrent) Technology and related product candidates.

Forward Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our Company's expectations and projections. The most significant of such risks and uncertainties include, but are not limited to, our ability, and the ability of King Pharmaceuticals Research and Development, Inc. and other pharmaceutical companies, if any, with whom we may license our Aversion(R) Technology, to obtain necessary regulatory approvals and commercialize products utilizing the Aversion(R) Technology, the ability to avoid infringement of patents, trademarks and other proprietary rights or trade secrets of third parties, and the ability to fulfill the FDA's requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the clinical studies completed to date and the results of other clinical studies, to support FDA approval of our product candidates, the adequacy of the development program for our product candidates, changes in regulatory requirements, adverse safety findings relating to our product candidates, the risk that the FDA may not agree with our analysis of its clinical studies and may evaluate the results of these studies by different methods or conclude that the results of the studies are not statistically significant, clinically meaningful or that there were human errors in the conduct of the studies or otherwise, the risk that further studies of our product candidates are not positive, and the uncertainties inherent in scientific research, drug development, clinical trials, the regulatory approval process, and commercial supply. You are encouraged to review other important risk factors relating to our operations on our web site at http://www.acurapharm.com under the link, "Company Risk Factors" and detailed in our filings with the Securities and Exchange Commission. We assume no obligation to update any forward-looking statements as a result of new information or future events or developments. Our press releases may be reviewed at http://www.acurapharm.com.


'/>"/>
SOURCE Acura Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion(R) (Abuse-Deterrent) Technology
2. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
3. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
4. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
9. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
10. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
11. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... provost of Liberty University, has officially announced the appointment of Peter A. Bell, ... College of Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to ...
(Date:2/24/2017)... ... , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” ... paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles with ... Schanssema, initially unsure of the career path he wanted to take, found fulfillment in ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced ... the Chairman of the Management Committee when IFN was originally formed in 2002 where ... investor/owners and development of the business plan. He became the first paid employee ...
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... Chapel Hill, NC (PRWEB) , ... February 23, 2017 , ... ... the Platinum Sponsor for ACPA’s 74th Annual Meeting. KLS is a longtime supporter ... in 2017 as an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Following receiving ... , s AMAR is a major milestone for the ... M w ound care market in ... BST for inclusion in the National Health Basket , ...   E-QURE Corp. (OTCQB: EQUR), a leader in medical devices ...
(Date:2/24/2017)... Feb 24, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Hemophilia Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Hemophilia market? ...
(Date:2/24/2017)... Feb. 24, 2017 Medical information groups ... increase their self-service capabilities to manage inquiries from ... New research from consulting leader Best ... developed self-service website portals where HCPs can sign ... one of many findings to emerge from the ...
Breaking Medicine Technology: